Comparison
Cagrilintide vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
1415456-99-3
2179963-22-7
Molecular weight
4253.7 g/mol
4727 g/mol
Half-life
168 h
168 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
2
of which in humans
3
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2